Changes In Genetic Markers Before And After Neoadjuvant Chemotherapy In Peripheral Blood Of Breast Cancer Patients

ObjectiveThis study is to detect the expression of cytokeratin-19(CK19)and human mammaglobin (hMAM) and the relationship between clinical indicator before and after neoadjuvant chemotherapy (NAC) in peripheral blood of breast cancers, to explre the significance of change with NAC, and to provide some theoris and clinical evidence to personalized NAC medicine.MethodQuantitative reverse transcriptase PCR(q-RT-PCR) was used to detect the expressions of CK19and hMAM before, after two and four weeks NAC in peripheral blood of43breast cancer patients,20benign breast disease and20healthy volunteers.Results1.The difference between the expression of CK19and hMAM in peripheral blood of breast cancer patients and benign breast disease and healthy volunteers has statistics meaning;2.In total of43, before NAC, the positive expression rates of CK19and hMAM in breast cancer patients were37.21%(]6/43)和41.86%(18/43); after combineing measurement of them, the positive expression rates is65.12%, which is higher than single gene;3.The positive expression of CK19and hMAM was correlated with clinical stages, lymph node metastasis,and not correlated with ages, menopause state, tumor size, estrogen receptor(ER) and progesterone receptor(PR);4.After2weeks'NAC, the positive expression of CK19and hMAM declined, which has statistics meaning:the positive patients of CK19reduced to5, before NAC the expression was10.803times as much as after it; and the patients of hMAM reduced to8, the expression was11.443times than after NAC. After4weeks, the positive patients of CK19reduced to3, before NAC the expression was0.822times than2weeks; and the positive patients of hMAM reduced to6, the expression was0.944times than after NAC, but there was no significant statistics meaning.Conclusions1.Combineing measurement of CK19and hMAM increased CTC expression rate in peripheral blood of breast cancer patients by qRT-PCR;2.Expression of CK19and hMAM was related to clinical stages and lymph node, and NAC reduced their expression;3.Reducing expression in CK19and hMAM in objeetive clieinal response patients higher than nonrespons patients, which pointed that changes of them is in accordance with clinical efficacy, which can show the function of NAC in killing micrometastasis in peripheral blood of breast cancer by combining exchanges of CK19and hMAM.